Arisa Akashi Sin
Lawyers
Filters
European Biotech Acquisition $200 million combination with Oculis
We are advising European Biotech Acquisition Corp. on its deSPAC transaction
Solid Biosciences $75 million common stock PIPE offering
The financing is taking place concurrently with the company’s acquisition of AavantiBio
Tellurian $500 million registered direct offering
The convertible senior secured notes are due 2025
Virgin Acquisition Corp. II $1.5 billion combination with Grove Collaborative
We are advising Virgin Acquisition Corp. II on the transaction
Tellurian $50 million senior notes offering
The 8.25% investment-grade notes are due 2028
Nuvei $425 million U.S. IPO
We advised Nuvei on its U.S. IPO and Nasdaq listing of subordinate voting shares
Brilliant Earth Group $115 million IPO
We advised the underwriters on the IPO and Nasdaq listing
PGT Innovations $575 million notes offering
We advised PGT Innovations on the high-yield debt offering
Tellurian $100.7 million stock offering
We advised the underwriter on the equity offering
Century Therapeutics $242.7 million IPO
We advised the underwriters on the IPO and Nasdaq listing